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Abstract
Introduction. Tumor extent (T stage) and lymph node involvement (N stage) have a known combined negative effect on
survival in patients with gallbladder adenocarcinoma, but the independent effects of these factors have been less well
described. We investigated whether T stage and N stage independently predict survival after surgery for gallbladder
adenocarcinoma. Methods. We queried the Surveillance, Epidemiology and End Results database for patients treated with
surgical resection for gallbladder adenocarcinoma between 1988 and 2004. Cases were stratified by disease severity based
on tumor extent and nodal involvement. KaplanMeier and Cox regression methods were used to test the effect of disease
severity and to develop multivariate models of the effects of demographic and clinical covariates on survival. Univariate and
multivariate models were tested in the entire cohort and in a subsample with pathologically confirmed lymph node status.
Results. Four thousand and forty-eight patients who survived the immediate perioperative period comprised the full cohort.
The subsample with pathologically confirmed lymph node status included 1298 patients. Age, gender, radiation treatment,
tumor grade, tumor extent and lymph node status had statistically significant independent effects on survival in both models
(all pB0.03). After accounting for T by N stage interactions, both tumor extent (1.215HR53.81, all p50.005) and
lymph node involvement (1.805HR52.84, pB0.001) had independent effects on survival. Conclusions. Tumor extent and
lymph node metastases are independent predictors of survival after surgical resection for gallbladder adenocarcinoma.
Tumor penetration of the gallbladder wall and pathologically confirmed lymph node involvement each carry poor prognosis.
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Introduction
Gallbladder adenocarcinoma is an aggressive malig-
nancy with a generally poor prognosis. Primary R0
surgical resection remains the best treatment option.
Five-year survival rates in the 1990s, based on
American Joint Committee on Cancer (AJCC) 5th
edition staging criteria, were 60% for Stage 0, 39% for
Stage I, 15% for Stage II, 5% for Stage III and 1% for
Stage IV [1]. Recent advances in surgical technique
and perioperative care have improved survival after
extensive local resections. There is an ongoing im-
petus for an aggressive surgical approach aimed at an
R0 resection. Currently most hepatobiliary surgeons
advocate radical liver and portal lymph node resec-
tions [2]. Some surgical centers suggest even more
radical resections, including combination hepatect-
omy with pancreaticoduodenectomy and radical
lymph node dissections including peripancreatic and
extended portal dissections [3]. With implementation
of an aggressive surgical resection technique, Dixon
et al. have shown an overall five-year survival im-
provement from 7 to 35% and a significant improve-
ment at every stage [2].
Tumor extent (T stage) and lymph node involve-
ment (N stage) significantly impact survival in
patients with gallbladder adenocarcinoma. Some
authors suggest that the T stage is the critical
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prognostic factor in gallbladder adenocarcinoma
[4,5]. However, others point to nodal metastasis as
the crucial indicator of long-term survival [6,7]. We
investigated the independent effects of tumor extent
and lymph node involvement on survival after surgical
resection for gallbladder adenocarcinoma. We were
also interested in analyzing the effect of radical
surgical resection on survival in patients with various
T and N stages of gallbladder cancer. To obtain an
adequate sample to answer these questions we ana-
lyzed data from the Surveillance, Epidemiology and
End Results (SEER) registry database for 19882004.
SEER data previously have demonstrated improved
survival in patients with gallbladder cancer who were
treated with adjuvant radiation therapy [8]. Analysis
of the SEER database has also suggested a decreasing
incidence and improved survival over the past three
decades of treatment of gallbladder cancer [9]. An-
other SEER registry study suggested the importance
of lymph node dissection in improving staging and
treatment [10]. We hypothesized that both increased
T stage and N stage would pose independent in-
creased risk of death. Using the SEER registry data,
we examined the association between extent of tumor
progression and lymph node involvement on survival
in patients with gallbladder adenocarcinoma.
Patients and methods
Surveillance, Epidemiology and End Results (SEER)
registry and study population
The SEER program is a United States population-
based cancer registry supported by the National
Cancer Institute and Centers for Disease Control
and Prevention spanning 19732004. The current
registry contains data from 18 sites and samples about
26% of the US population. SEER registrars routinely
collect demographic data, primary tumor character-
istics including tumor site and spread, primary course
of treatment exclusive of chemotherapy, and follow-
up for vital status [11].
Data collection and management
This investigation was reviewed and approved by
Vanderbilt University Medical Center Institutional
Review Board. We conducted a retrospective, popula-
tion-based cohort analysis of patients listed in the
SEER database who underwent surgical resection for
pathologically confirmed diagnosis of gallbladder
adenocarcinoma (SEER specific icd-o-3 code 8140
and primary pathology site code C23.9-gallbladder)
between 1988 and 2004. Demographic data included
age, gender, race, and ethnicity. Clinical staging data
included AJCC tumor/node/metastasis (TNM) sta-
ging (Table I), available for 2004, and extent of
disease (EOD10) classification, available for the years
19882003. Data regarding tumor grade, radiation
therapy, extent of surgical resection and survival were
also recorded. Surgical eras were classified as either
19881996 or 19972004 based on perceived use of
aggressive surgical resection in clinical practice.
The EOD10 data were recoded into the TNM
staging paradigm using the SEER EOD10 coding
manual and AJCC Staging Manual 6th edition [12
14]. Patients with missing staging information were
excluded from the study. Additionally, those patients
who were recorded in the SEER registry as being
deceased before one month of follow-up were coded
as a perioperative death and were excluded from
analysis. Only those patients with pathologically
confirmed node positive disease were identified as
having lymph node involvement. Patients with docu-
mented node negative disease, as well as patients
without pathologically examined lymph nodes or
without nodes present in the specimen were categor-
ized as node negative. A separate subsample analysis,
which was restricted to the patients with pathologi-
cally examined lymph nodes, was also performed.
SEER registry coding for surgical interventions is
based on local interventions, simple/partial surgical
resections, total surgical removal, debulking opera-
tions, or radical resections. We reclassified these
surgery codes as local, total, or radical resections
based on SEER manual definitions [14]. SEER
EOD10 tumor extent code ‘‘70’’, defined in the
manual as either ‘‘extension into liver 2 cm or
extension into two or more adjacent organs or liver
involvement with any other organ’’, could be inter-
preted as either a T3 or T4 lesion. Preliminary
analysis confirmed these patients to have survival
similar to the T4 lesion patients. Therefore, patients
with EOD10 tumor extent code ‘‘70’’ were grouped
with Stage III patients. The final classification system
for disease severity based on clinical stage, tumor
extent, and nodal involvement comprised eight mu-
tually exclusive strata: Stage IA, Stage IB, Stage IIA,
Table I. American Joint Committee on Cancer (AJCC) 6th edition
staging system [12].
Stage TNM classification
Stage IA T1, N0, M0
Stage IB T2, N0, M0
Stage IIA T3, N0, M0
Stage IIB T1-3, N1, M0
Stage III T4, N any, M0
Stage IV T any, N any, M1
Note: T1, tumor invades lamina propria or muscle layer; T2, tumor
invades the perimuscular connective tissue, no extension beyond the
serosa or into the liver; T3, tumor perforates the serosa (visceral
peritoneum) and/or directly invades the liver and/or one other
adjacent organ or structure, such as the stomach, duodenum, colon,
or pancreas, omentum or extrahepatic bile ducts; T4, tumor invades
main portal vein or hepatic artery or invades multiple extrahepatic
organs or structures; N0, no regional lymph node metastasis; N1,
regional lymph node metastasis; M0, no distant metastasis; M1,
distant metastasis.
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Stage IIB  T1N1, Stage IIB  T2N1, Stage IIB
 T3N1, Stage III, and Stage IV.
Statistical analysis
KaplanMeier survival analysis, with the Log-rank
test for between-group comparisons, was used to test
the effect of the disease severity classification system
on survival [15,16]. Cox proportional hazards regres-
sion was used to develop a multivariate models of the
effects of age, sex, race, ethnicity, radiation therapy,
tumor grade, tumor extent, lymph node status, extent
of resection, and era of operation on survival in
patients without metastatic disease [17]. A T stage
by N stage interaction effect was included in the Cox
multivariate models. Two separate univariate and
multivariate analyses were performed. The first ana-
lysis tested the effects in the entire cohort. The second
analysis tested the effects in the subsample of patients
with pathologically confirmed lymph node status.
STATA10 data analysis and statistical software
(College Station, TX) was used in data management,
statistical analysis and graphics design. A Type I error
probability of B0.05 was considered statistically
significant. Summary data are reported as mean9
SD or percentages.
Results
Demographics
There were 5944 patients in the SEER database
diagnosed with gallbladder adenocarcinoma between
1988 and 2004. From this group 4365 patients
underwent surgical treatment for gallbladder adeno-
carcinoma and 4048 patients (93%) had sufficient
staging information recorded in the SEER database
and survived the immediate perioperative period.
These 4048 patients comprised the complete cohort
for further analysis. Demographic and clinical data are
summarized in Table II. Patients averaged 71913
years. Among the patients 74% were female, 81%
were Caucasian and 17% were of Hispanic ethnicity.
Radiation therapy was received by 18% of the
patients. Specific tumor grade and TNM stage
information are shown in Table II.
Only 1298 patients (32%) of the full cohort group
had pathologically examined lymph nodes. This
subsample was examined separately as a secondary
analysis. Demographic and clinical data in this patient
subsample were comparable to the overall cohort,
with the exception of the proportion of patients with
lymph node involvement (Table II). In both samples,
737 patients had positive lymph nodes. In the overall
cohort, this constituted 18% of the patients, while in
the subsample analysis these patients comprised 57%
of the population.
Univariate analyses
The effect of disease severity on survival is summar-
ized in Table III. In the full study cohort, one- and
five-year survival estimates based on KaplanMeier
analysis were better for Stage IA (72 and 37%), Stage
IB (66 and 29%), Stage IIB  T1N1 (53 and 18%)
and Stage IIB  T2N1 (69 and 21%) disease; than for
Stage IIA (40 and 10%), Stage IIB  T3N1 (43 and
7%), Stage III (21 and 3%) and Stage IV (11 and 3%)
disease. Interestingly, in this cohort, patients with
Stage IIB  T1N1 and Stage IIB  T2N1 survived
significantly longer than patients with Stage IIA
disease. Pairwise comparisons revealed improved
median survival from Stage IIA: nine month to Stage
IIB  T1N1: 14 month (p0.037) and improved
median survival from Stage IIA: nine month to Stage
IIB  T2N1: 21 month (pB0.001). Survival did not
differ between Stage IIA: nine month and Stage IIB 
T3N1: 11 month (p0.634). One- and five-year
survival proportions were similarly improved in pa-
tients with Stage IIB  T1N1 and Stage IIB  T2N1
disease compared to patients with Stage IIA disease
(Table III). Survival curves for Stage IA through Stage
IIB are shown in Figure 1.
Univariate analysis for the subsample of patients
with pathologically confirmed lymph node status
differed in specific respects from the full cohort (Table
III). KaplanMeier one- and five-year survival esti-
mates in patients with pathologically confirmed lymph
node status were better for patients with Stage IA (84
and 47%) and Stage IB (88 and 54%) disease, than
for those with Stage IIA (65 and 23%), Stage IIB 
T1N1 (53 and 18%), Stage IIB  T2N1 (68 and
21%), Stage IIB  T3N1 (43 and 6%), Stage III (29
and 8%), and Stage IV (21 and 4%) disease. Pairwise
comparisons did not reveal statistically significant
differences between patients with Stage IA and Stage
IB disease (p0.423). Survival in this subsample was
Table II. Demographic and clinical data: SEER database, cases
entered 19882004.
Full study cohort
4048 patients
Pathologically confirmed
LN 1298 patients
Age 71913 68913
Female 2990 (73.8%) 952 (73.3%)
Caucasian 3282 (81.1%) 1,049 (80.8%)
Hispanic 686 (17.0%) 206 (15.9%)
Radiation 726 (17.9%) 338 (26.0%)
Grade I 561 (13.9%) 160 (12.3%)
Grade II 1546 (38.2%) 496 (38.2%)
Grade III 1508 (37.3%) 517 (39.8%)
Grade IV 58 (1.4%) 29 (2.2%)
T1 907 (22.4%) 248 (19.1%)
T2 809 (20.0%) 297 (22.9%)
T3 1339 (33.1%) 477 (36.7%)
T4 233 (5.8%) 79 (6.1%)
Lymph node in-
volvement
737 (18.2%) 737 (56.8%)
Metastatic 845 (20.9%) 231 (17.8%)
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better in Stage IIA patients compared to patients with
Stage IIB  T1N1 disease (p0.041) and patients
with Stage IIB  T3N1 disease (pB0.001). It did not
differ between patients with Stage IIA and Stage IIB 
T2N1 disease (p0.960). Survival curves for the
subsample analysis between Stage IA and Stage IIB
are shown in Figure 2.
Multivariate analysis
The multivariate Cox model testing of the indepen-
dent effects of tumor extent and lymph node involve-
ment on survival in 2930 patients without metastatic
disease is summarized in Table IV. Of the 3203
patients with non-metastatic disease, 273 patients
were excluded from multivariate analysis due to either
missing tumor grade or surgical procedure. This
model demonstrates statistically significant indepen-
dent risk of death in patients with progressive tumor
extent and node positive disease. Additionally, in-
creasing age, male gender, African American race,
increasing tumor grade, increasing tumor extent, and
presence of lymph node involvement all conferred
independent risk of death in patients with gallbladder
adenocarcinoma (all pB0.04). Radiation treatment
conferred 22% risk reduction in this model (pB
0.001). There was a greater independent risk asso-
ciated with progressive tumor extent (HR1.21,
CI1.051.39, p0.008 for T2 vs. T1; HR2.29,
CI2.022.59, pB0.001 for T3 vs. T1 and HR
3.81, CI3.144.62, pB0.001 for T4 vs. T1) than
associated with lymph node involvement (HR1.80,
CI1.372.37, pB0.001).
A separate multivariate model was developed for
the subsample of patients with pathologically con-
firmed lymph node status without distant metastases.
Of the 1067 patients without distant metastases, 999
had complete data and were included in the multi-
variate analysis. Age, male gender, increasing tumor
grade, increasing tumor extent and lymph node
involvement all conferred statistically significant in-
dependent risk of death (all pB0.01). Radiation
Table III. One- and five-year survival by disease severity stratification.
Full study cohort 4048 patients Pathologically confirmed LN 1298 patients
Disease severity No. of patients One-year (%) Five-year (%) No. of patients One-year (%) Five-year (%)
Stage IA 814 72.1 36.6 160 84.2 47.4
Stage IB 659 65.3 28.5 155 88.0 53.8
Stage IIA 982 39.6 10.3 155 65.5 24.9
Stage IIB  T1N1 86 52.7 18.2 86 52.7 18.2
Stage IIB  T2N1 135 68.6 20.7 135 68.6 20.7
Stage IIB  T3N1 298 43.0 6.5 298 43.0 6.5
Stage III 229 21.2 2.9 78 28.9 7.9
Stage IV 845 11.3 2.6 231 21.1 4.5
Figure 1. Survival by disease severity in the full study cohort. Patients with Stage IA through Stage IIB disease are included in the Kaplan
Meier plot. Survival estimates were significantly better for patients with Stage IA, Stage IB, Stage IIB  T1N1, and Stage IIB  T2N1
disease; than for patients with Stage IIA, and Stage IIB  T3N1 disease.
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therapy conferred a 35% risk reduction (pB0.001),
and patients undergoing operation after 1997 had an
18% risk reduction compared to patients treated
before 1997 (p0.022). In this model, the indepen-
dent effect of lymph node involvement (HR2.84,
CI1.994.04, pB0.001) was more pronounced
than in the full cohort. Tumor extent at the T2 level
did not convey additional risk (p0.626); however
both T3 (HR2.13, CI1.552.91, pB0.001) and
T4 (HR3.23, CI 1.975.31) lesions conveyed
significant independent risks (Table IV).
Both models included significant T stage by N stage
interaction effects (pB0.05) which reflected increased
risk due to lymph node involvement across progres-
sion of tumor extent. These interaction effects pro-
duced a non-multiplicative combination of T stage
and N stage risk that is summarized in Table V. In the
full cohort, T stage contributes significant risk at
every level, while the effect of N stage provided
considerably less additional risk. The additional risk
due to nodal involvement was greatest in patients with
T1 stage disease. However, the negative effect of N
Figure 2. Survival by disease severity in the patient subsample with pathologically confirmed lymph node status. Survival estimates were
significantly better for patients with Stage IA and Stage IB disease, than for patients with Stage IIA, Stage IIB  T1N1, Stage IIB  T2N1,
and Stage IIB  T3N1 disease.
Table IV. Cox multivariate model of the effects of clinical and demographic covariates on survival.
Full study cohort 2930 patients Pathologically confirmed LN 999 patients
HR 95% CI P-value HR 95% CI P-value
Age at diagnosis 1.02 1.011.03 B0.001 1.02 1.011.03 B0.001
Female sex 0.88 0.800.96 0.006 0.79 0.670.94 0.007
African American race 1.20 1.011.41 0.033 0.99 0.711.37 0.946
Hispanic ethnicity 0.99 0.881.11 0.827 1.04 0.841.29 0.710
Radiation 0.78 0.700.87 B0.001 0.65 0.540.79 B0.001
Surgery
Total vs. Local 0.99 0.841.17 0.898 0.87 0.641.18 0.369
Radical vs. Local 0.91 0.751.11 0.352 0.85 0.611.20 0.354
Era (19972004 vs. 198896) 0.93 0.851.02 0.115 0.82 0.700.97 0.022
Tumor grade
II vs. I 1.27 1.111.44 B0.001 1.28 0.991.66 0.064
III vs. I 1.84 1.612.10 B0.001 1.71 1.322.22 B0.001
IV vs. I 2.00 1.422.82 B0.001 2.13 1.273.57 0.004
Tumor extent (T stage)
T2 vs. T1 1.21 1.051.39 0.008 0.92 0.641.31 0.626
T3 vs. T1 2.29 2.022.59 B0.001 2.13 1.552.91 B0.001
T4 vs. T1 3.81 3.144.62 B0.001 3.23 1.975.31 B0.001
LN involvement (N stage) 1.80 1.372.37 B0.001 2.84 1.994.04 B0.001
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stage was more pronounced in patients with the
pathologically confirmed lymph node status. In this
subsample, the incremental risk of nodal metastases
was significant at every T stage, and was most
pronounced for T1 and T2 lesions.
Impact of surgery
The type of surgical interventions was recoded from
the SEER registry as three groups (local, total, and
radical) and included in the multivariate model. In the
full study cohort, after excluding patients with meta-
static disease, the number of patients in the three
groups was: local n295 (9.2%), total n2,474
(77.2%), or radical n411 (12.8%). Twenty-three
patients (0.7%) did not have a specific operative code
recorded. We did not demonstrate a significant
difference in survival due to either total vs. local
resection (HR0.99, CI0.841.17, p0.898) or
radical vs. local resection (HR0.91, CI0.751.11,
p0.352). Distribution of operative procedures was
similar between the full cohort and in the subsample
of patients with pathologically confirmed lymph node
status. Consistent with the findings in the full cohort,
neither total vs. local resection (HR0.87, CI
0.641.18, p0.369) nor radical vs. local resection
(HR0.82, CI0.700.97, p0.354) provided a
statistically significant benefit in this subsample.
Discussion
Gallbladder adenocarcinoma continues to present
challenges in diagnosis and treatment. Most patients
with symptomatic gallbladder malignancy present
with incurable, advanced stage, disease [18]. A
number of single-center studies suggest improved
outcomes with aggressive surgical management
[2,3]. The goal of surgical treatment of gallbladder
carcinoma is complete R0 tumor resection with
negative histologic margins. While the rationale for
extended cholecystectomy as well as hemi- or ex-
tended hepatectomy and portal lymph node dissection
has been universally accepted among hepatobiliary
surgeons, the efficacy of more radical procedures
including extrahepatic biliary resection, radical lymph
node dissection, and pancreaticoduodenectomy has
remained controversial [19]. A number of studies
document improved survival with aggressive resec-
tions for patients with T2, T3 and even T4 lesions
[7,20,21]. Other studies suggest success of lympha-
denectomy in improving survival in patients with N1
disease [22,23].
Our aim was to evaluate independent effects of
tumor extent and lymph node metastases on survival
in gallbladder adenocarcinoma. The SEER registry
provides a rich source of data for a population-based
cohort study. Unfortunately only 32% of all patients
undergoing surgical resection for gallbladder adeno-
carcinoma between 1988 and 2004 had pathologically
examined lymph nodes as part of the specimen.
Excluding these patients could markedly reduce the
representative distribution of the study sample and
would lead to a substantial loss of statistical power.
For these reasons we developed two separate analyses.
In the first analysis, we investigated the univariate and
multivariate effects in our full patient cohort. In the
second analysis we focused on those patients with
pathologically confirmed lymph node status. Tumor
extent and lymph node involvement exerted statisti-
cally significant independent negative effects on
patient survival in both analyses. Univariate effects
differed between the full cohort, in which patients
without pathologically documented lymph node sta-
tus were classified as N0, and the subsample of
patients with pathologically confirmed lymph nodes.
In the full cohort, univariate analysis suggested that
patients with Stage IIB T1N1 and Stage IIB T2N1
had better survival than patients with Stage IIA
 T3N0. However, this finding did not persist in the
subsample of patients with confirmed N stage. In fact,
patients with T1N0 and T2N0 lesions had compara-
tively better survival to patients with either T3 lesions
or N1 lesions. This finding implies that a number of
patients with undocumented lymph node status
included in the T3N0 group in the full cohort actually
had N1 lesions. Subsample analysis confirmed that
155 patients in T3N0 group had pathologically
confirmed negative lymph nodes, which leaves 827
patients from the full cohort with undocumented
lymph node status. Unfortunately it is impossible to
determine which of these patients from the full cohort
have N0 or N1 lesions.
Table V. Effect of T stage and N stage on survival in patients with gallbladder adenocarcinoma without distant metastases  interaction
model adjusted for age, sex, race, ethnicity, radiation therapy, extent of surgery, era of operation and tumor grade. Data entries are hazard
ratios (95% CI).
Full study cohort Pathologically confirmed LN
N0 N1 N0 N1
T1 1.0* 1.80 (1.372.37) 1.0* 2.84 (1.994.04)
T2 1.21 (1.051.39) 1.44 (1.141.83) 0.92 (0.641.31) 2.26 (1.633.13)
T3 2.29 (2.022.59) 2.35 (1.972.77) 2.13 (1.552.91) 3.75 (2.824.97)
T4 3.81 (3.144.62) 3.85 (2.765.37) 3.23 (1.975.31) 6.77 (4.4810.23)
*HR 1.0 for T1N0 used as reference.
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However, the multivariate analyses were more
consistent between the overall cohort and the sub-
sample of patients with pathologically confirmed
lymph node status. Both multivariate models included
significant T stage by N stage interaction effects and
demonstrated significant independent effects of tumor
extent and lymph node involvement on survival in
gallbladder adenocarcinoma. In patients without dis-
tant metastatic disease, both models demonstrated
that lymph node involvement conferred a significantly
increased risk of death, while the presence of a T3
lesion more than doubled and a T4 lesion more than
tripled this risk. The effect of T2 lesions was
statistically significant in the full model, but not in
the subsample analysis. The effect of N1 stage in the
full model increased the risk by 80%, but almost
tripled the risk in the patients with pathologically
confirmed lymph nodes.
In the full cohort, hazard ratios increased substan-
tially with increase in T stage, but increased only
slightly with lymph node involvement. However, in
patients with documented lymph node status, lymph
node involvement conveyed a substantially increased
risk across the T stages. Once more, this finding
implies that a number of patients with undocumented
lymph node status may have had N1 disease. Given
that these patients did not have documented meta-
static disease, we can only speculate as to why they did
not undergo a more aggressive lymph node dissection.
Unfortunately, the SEER registry for years 1988
2004 does not have sufficient information to test the
effect of an aggressive surgical approach in this patient
population with stringency. The coding of surgical
procedure is based on ‘‘completeness’’ of resection
and does not provide the specifics of the surgical
intervention. As such, the precise surgical interven-
tion, and whether the planned intervention was an R0
resection with an intent to cure, is unknown. We
characterized operative interventions as local, total,
and radical resections based on SEER coding and did
not show a significant impact on survival in the
multivariate models. Interestingly, only 12.8% of the
patients without distant metastatic disease underwent
a radical resection. It is not known how many patients
were diagnosed after a routine cholecystectomy and
required re-resections as part of treatment.
As we have documented, in the SEER registry, only
32% of the patients surgically treated for gallbladder
adenocarcinoma had pathologically documented pre-
sence of lymph nodes within the resection specimen.
Moreover, only about 13% of the patients underwent
aggressive surgical treatment. Yet, our analysis sug-
gests that tumor penetration through the gallbladder
wall and pathologically documented lymph node
involvement each carry a particularly poor prognosis
in this patient population. While the evidence is
indirect, we believe that these data suggests that
lymph node status must be better documented at
the time of resection with a more thorough regional
lymphadenectomy. In addition, in an attempt to
improve survival, patients with T3 lesions must be
treated with a radical resection.
The SEER registrars are continually striving to
improve the quantity and quality of data within the
database. While this cancer database is the standard
for quality among cancer registries in USA, some of
the patient and treatment information is limited. The
registry includes data from both community and
academic hospitals; however, information is not
stratified by hospital type or volume of complex
biliary procedures. As with other complex hepato-
pancreato-biliary procedures, it is likely that the
multimodality treatment and high surgical volume
would lead to improved outcomes [24,25]. Some of
the tumor staging and grading data is missing. As
previously discussed, information regarding operative
procedure lacks specificity and cannot be used to
identify an operative procedure. Information about
patients’ comorbidities, performance status, tumor
resection margin, and chemotherapy is not available.
Despite these limitations, well-designed SEER regis-
try studies have provided clinicians with a wealth of
information. Continuous improvements in SEER data
collection and management will increase utility of this
registry in study of quality and outcomes in cancer
treatment.
Our study, based on population data captured by
the SEER registry between 1988 and 2004, demon-
strates that both tumor extent and lymph node
metastases are independent predictors of survival in
gallbladder adenocarcinoma. Patients with tumor
extent limited to the perimuscular connective tissue
without positive lymph nodes had best prognosis.
Tumor penetration of gallbladder wall and pathologi-
cally confirmed lymph node involvement carried
particularly poor prognosis.
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